Cargando…

Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control

BACKGROUND: The prognostic benefits of beta-blockers (BB) in patients with systolic heart failure (SHF) are known but despite this, in patients with diabetes they are underutilized. The aim of this study was to assess the effect of beta-blockers (BB) on glycaemic control in patients with Type 2 Diab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wai, Bryan, Kearney, Leighton G, Hare, David L, Ord, Michelle, Burrell, Louise M, Srivastava, Piyush M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298480/ https://www.ncbi.nlm.nih.gov/pubmed/22330091 http://dx.doi.org/10.1186/1475-2840-11-14

Ejemplares similares

The CTGF gene −945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes
por: Patel, Sheila K, et al.
Publicado: (2012)

Augmented glycaemic gap is a marker for an increased risk of post-infarct left ventricular systolic dysfunction
por: Zhu, Yong, et al.
Publicado: (2020)

Beta-Blockers in the Critically Ill: Friend or Foe?
por: Senussi, Mourad H.
Publicado: (2021)

Implications of renin‐angiotensin‐system blocker discontinuation in acute decompensated heart failure with systolic dysfunction
por: Darden, Douglas, et al.
Publicado: (2019)

The duration of beta‐blocker therapy and outcomes in patients without heart failure or left ventricular systolic dysfunction after acute myocardial infarction: A multicenter prospective cohort study
por: Wen, Xue‐Song, et al.
Publicado: (2022)

Beta‐blocker use and mortality among patients with systolic heart failure and pacemaker rhythm
por: Perry, Andrew S., et al.
Publicado: (2023)

Clinical features of subclinical left ventricular systolic dysfunction in patients with diabetes mellitus
por: Mochizuki, Yasuhide, et al.
Publicado: (2015)

Beta-blockers Associated with a Mortality Benefit in Patients with Systolic Dysfunction and Elevated Serum Bilirubin
por: Labos, Christopher, et al.
Publicado: (2014)

A clinical study about contrast nephropathy: Risk factors and the role of beta blockers
por: Akgüllü, Çağdaş, et al.
Publicado: (2015)

Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients
por: Dungan, Kathleen, et al.
Publicado: (2019)

Subjective Evaluation of Right Ventricular Systolic Function in Hypoplastic Left Heart Syndrome: How Accurate Is It?
por: Bellsham-Revell, Hannah R., et al.
Publicado: (2013)

Lack of correlation between the optimal glycaemic control and coronary micro vascular dysfunction in patients with diabetes mellitus: a cross sectional study
por: Valenzuela-Garcia, Luis Felipe, et al.
Publicado: (2015)

Beta Blocker Use After Acute Myocardial Infarction in the Patient with Normal Systolic Function: When is it “Ok” to Discontinue?
por: Kezerashvili, Anna, et al.
Publicado: (2012)

Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT)
por: Cohen, Jordana B., et al.
Publicado: (2022)

Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes
por: Swoboda, Peter P., et al.
Publicado: (2018)

Association between intrarenal arterial resistance and diastolic dysfunction in type 2 diabetes
por: MacIsaac, Richard J, et al.
Publicado: (2008)

Beta-blocker therapy in patients with left ventricular systolic dysfunction and chronic obstructive lung disease in an ambulatory care setting
por: Schimmer, Jennifer J., et al.
Publicado: (2009)

Beta‐blockers for hypertension
por: Wiysonge, Charles S, et al.
Publicado: (2017)

Beta-blockers in sepsis
por: Singer, Mervyn
Publicado: (2019)

Beta Blockers and Melanoma
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

HaploBlocker: Creation of Subgroup-Specific Haplotype Blocks and Libraries
por: Pook, Torsten, et al.
Publicado: (2019)

An unusual toxicity with beta blocker and calcium channel blocker
por: Anand, Vijay, et al.
Publicado: (2015)

Diabetes mellitus, glycaemic control, and severe COVID-19 in the Australian critical care setting: A nested cohort study
por: Plummer, Mark P., et al.
Publicado: (2023)

Type 1 diabetes mellitus abrogates compensatory augmentation of myocardial neuregulin-1β/ErbB in response to myocardial infarction resulting in worsening heart failure
por: Odiete, Oghenerukevwe, et al.
Publicado: (2013)

Pattern of the Heart Rate Performance Curve in Subjects with Beta-Blocker Treatment and Healthy Controls
por: Birnbaumer, Philipp, et al.
Publicado: (2021)

Worsening renal function in hospitalized patients with systolic heart failure: prevalence and risk factors
por: Asbagh, Amirhosein Ghafouri, et al.
Publicado: (2023)

Perioperative use of beta-blockers
por: Priebe, Hans-Joachim
Publicado: (2009)

Beta-blockers in liver cirrhosis
por: Giannelli, Valerio, et al.
Publicado: (2014)

Short-term follow-up of exercise training program and beta-blocker treatment on quality of life in dogs with naturally acquired chronic mitral valve disease
por: Marcondes-Santos, M., et al.
Publicado: (2015)

Early Detection of Left Ventricular Systolic Dysfunction Using Two-Dimensional Speckle Tracking Strain Evaluation in Healthy Subjects after Acute Alcohol Intoxication
por: Reant, Patricia, et al.
Publicado: (2012)

Duration of type 2 diabetes mellitus and systolic blood pressure as determinants of severity of coronary stenosis and adverse events in an asymptomatic diabetic population: PROCEED study
por: Venuraju, Shreenidhi M., et al.
Publicado: (2019)

Worsening Cardiovascular Disease Epidemiology in the United States: The Time for Preparation Is Now
por: Kalogeropoulos, Andreas P., et al.
Publicado: (2022)

The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control
por: Casanova, F., et al.
Publicado: (2017)

A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure
por: Iyngkaran, Pupalan, et al.
Publicado: (2016)

The adverse impact of coronary artery disease on left ventricle systolic and diastolic function in patients with type 2 diabetes mellitus: a 3.0T CMR study
por: Wang, Jin, et al.
Publicado: (2022)

Certainties fading away: β-blockers do not worsen chronic obstructive pulmonary disease
por: Verdecchia, Paolo, et al.
Publicado: (2021)

Exercise worsening of electromechanical disturbances: A predictor of arrhythmia in long QT syndrome
por: Charisopoulou, Dafni, et al.
Publicado: (2018)

Calcium-Channel Blockers: An Alternative Therapy to Beta-Blockers for Myocardial Infarction?
por: Hao, Kiyotaka, et al.
Publicado: (2023)

Increased myocardial extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain
por: Cao, Yukun, et al.
Publicado: (2018)

Prevalence of left ventricular systolic dysfunction and heart failure with reduced ejection fraction in men and women with type 2 diabetes mellitus: a systematic review and meta-analysis
por: Bouthoorn, Selma, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_592kuh7j2d7751o7qkt2vclq0t